Table 3

Allopurinol use

Patient characteristics

No CKD

(N = 2,393)

Stage 2 CKD

(N = 1,032)

Stage 3 CKD

(N = 357)

Stage 4 CKD

(N = 147)

p-value


Used allopurinol during follow-up period, including index date

N

1,855

826

312

129

%

77.52

80.04

87.39

87.76

< .0001


Initial daily dose (mg)

N

1,855

826

312

129

Mean

248.17

249.02

233.78

217.63

0.0023

Std

107.41

107.45

103.73

104.55

Median

300

300

300

200


Last daily dose (mg)

N

1,552

699

260

109

Mean

268.93

261.63

248.08

241.54

0.0021

Std

106.46

102.43

94.11

127.4

Median

300

300

300

300


Difference between last dose and initial dose among subjects who titrated (mg)

N

269

108

53

36

Mean

106.02

102.73

66.26

86.33

0.5366

std

192.07

188.55

167.93

187.99


Subjects who titrated

n

270

108

53

36

%

14.56

13.08

16.99

27.91

0.00014


Increased between first and last dose

n

213

87

37

27

%

78.89

80.56

69.81

75

0.4253


Decreased between first and last dose

n

57

21

16

9

%

21.11

19.44

30.19

25

0.4253


Fuldeore et al. BMC Nephrology 2011 12:36   doi:10.1186/1471-2369-12-36

Open Data